Dompe and SatRx Team Up for Clinical Development of Innovative Drug for ... Marketwire (press release) The multi-center, open-label, randomized Phase II-III trials are prepared to assess the efficacy and safety of Reparixin in the prevention of early allograft dysfunction in liver transplanted patients. Patients for liver transplantation will be ... |
